Strategic acquisition expands US presence

Clean Cells, part of the Clean Biologics group and a leader in biopharmaceutical quality control services, has announced the strategic acquisition of Karyologic Inc., a specialised karyotyping services company based in Durham, North Carolina. This move marks a significant step in Clean Cells’ global growth strategy, establishing a direct operational presence in the US.

Karyologic, a trusted provider of cytogenetic testing services essential for biologics development and cell therapy products, will now enable Clean Cells to offer enhanced karyotype services to its North American clients. This acquisition strengthens the company's ability to bring its full range of services closer to US-based customers.

Joseph Jammal, CEO of Clean Cells, shared his excitement about the acquisition: “This milestone allows us to expand our operational footprint in the US, supporting our mission to drive innovation in biologics through exceptional service across Europe and North America.”

Elizabeth Gonzalez, CEO of Karyologic, expressed optimism about the future: “By joining forces with Clean Cells, we can combine our cytogenetic expertise with their comprehensive biologics services. This partnership will enhance the value and reliability we provide to clients globally.”

Denis Ribon, managing partner at ARCHIMED, Clean Cells' majority investor, also welcomed the move: “This acquisition is a key step in our strategy to expand Clean Cells’ international presence and strengthen its position in the fast-growing biologics market.”

The acquisition, finalised on 31 March 2025, kicks off a series of integration activities designed to utilise the combined strengths of both companies, enhancing service delivery and client support.

More information online